15679-10-4 Usage
Uses
Used in Flavor Industry:
2-Isopropylthiazole is used as a flavor compound for its ability to enhance savory and meaty flavors in food products. Its unique aroma profile contributes to the richness and depth of flavor in a variety of culinary applications.
Used in Fragrance Industry:
In the production of fragrances, 2-Isopropylthiazole is used as a scent ingredient to impart a roasted, coffee-like note. This adds complexity and a distinct character to perfumes and other scented products, making it a valuable component in the fragrance formulation process.
Safety:
2-Isopropylthiazole is considered safe for use in both food and fragrance applications when incorporated in appropriate concentrations, ensuring that it does not pose any health risks to consumers.
Check Digit Verification of cas no
The CAS Registry Mumber 15679-10-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,6,7 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 15679-10:
(7*1)+(6*5)+(5*6)+(4*7)+(3*9)+(2*1)+(1*0)=124
124 % 10 = 4
So 15679-10-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H9NS/c1-5(2)6-7-3-4-8-6/h3-5H,1-2H3
15679-10-4Relevant academic research and scientific papers
HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF
-
Page/Page column 128-129, (2019/11/12)
Disclosed are HPK-1 inhibitors having a structure represented by Formula (X), pharmaceutical compositions comprising the HPK-1 inhibitors, methods of using the HPK-1 inhibitors, such as treating cancers, methods of preparing the HPK-1 inhibitors, and the synthetic intermediates.
4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2
-
Page/Page column 47-48, (2010/06/19)
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).
